Clinical Trials Logo
  1. Home
  2. Neurotoxicity
  3. NCT00834496

Switching From One Type of Anti-rejection Drug (Tacrolimus or Cyclosporine) to Another (Sirolimus) Approximately 90-180 Days After Liver Transplantation

Neurotoxicity Clinical Trial

Official title:
Sirolimus Switching From Calcinurin Inhibitors (CNI) 90 - 180 Days After Liver Transplantation

Clinical Trial Summary

Sirolimus can be safely switched as early as 90 days after liver transplantation with excellent tolerability and amelioration of the calcineurin inhibitor toxicity that initiated the switch.

Clinical Trial Description

n/a

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00834496
Study type Observational
Source Thomas Jefferson University
Contact
Status Withdrawn
Phase N/A
Start date January 2009
Completion date January 2010
View Details
See also
  Status Clinical Trial Phase
Completed NCT05510596 - Magnetic Resonance Imaging in Immune Effector Cell-Associated Neurotoxicity Syndrome N/A
Completed NCT01399372 - Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma Phase 2
Completed NCT01196442 - Electrical Stimulation Pain Therapy in Treating Chronic Pain and Numbness Caused By Chemotherapy in Patients With Cancer N/A
Completed NCT00775645 - S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy Phase 3
Recruiting NCT00884767 - Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin Phase 2
Recruiting NCT03330964 - Clinical Trial of Electroacupuncture Stimulation on Prevention and Treatment of Oxaliplatin Neurotoxicity N/A
Active, not recruiting NCT04150913 - A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity Phase 2
Completed NCT01417507 - Natural History of Brain Function, Quality of Life, and Seizure Control in Patients With Brain Tumor Who Have Undergone Surgery N/A
Completed NCT00471445 - Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients Phase 3
Completed NCT00365768 - Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors Phase 2
Withdrawn NCT00734773 - Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL Phase 0
Completed NCT00305799 - Hearing Loss and Dizziness in Patients Receiving Oxaliplatin for Solid Tumors N/A
Completed NCT00018967 - Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate N/A
Active, not recruiting NCT00978458 - Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma Phase 3
Completed NCT05094154 - Effect of Antibiotic Choice On ReNal Outcomes (ACORN) Phase 4
Completed NCT02486198 - Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer Phase 3
Not yet recruiting NCT05798884 - Electro-acupuncture for the Prevention and Treatment of Oxaliplatin-induced Neurotoxicity in Colorectal Cancer Patients N/A
Completed NCT02864030 - PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment Phase 4
Completed NCT00369564 - Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer Phase 3
Completed NCT00755313 - Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer N/A